The process of cell microvesiculation is one of molecular mechanisms of COVID-19 coagulopathy. Correlation of microvesicals production, severity of disease and clinical manifestations of thrombosis, remains unclear.

GOAL OF THE STUDY

Determination of the nature and number of microvesicles of blood cells and endothelium in patients with moderate COVID-19 hospitalized in a hospital.

MATERIAL AND METHODS

The study included 43 patients hospitalized for moderate COVID-19 and grade 2 lung damage, compared with 14 controls without signs of acute respiratory infection and risk factors for thrombosis.

RESEARCH RESULTS

An increase in microvesicles of platelet, leukocyte, and erythrocyte origin (except for endothelial ones, which showed a decrease in comparison with the control) was revealed in the absence of an increase in the level of D-dimer in most patients. Positive dynamics was noted during the period of hospitalization against the background of pathogenetic therapy without normalization of the number of platelet microvesicles.

CONCLUSIONS

The high activity of microvesiculation in patients with moderate COVID-19 reflects the potential risk of thromboembolic complications even in the absence of an increased D-dimer level. The microvesiculation process correlates with the severity of the inflammatory response. Etiopathogenetic treatment with the inclusion of anticoagulants reduces the production of microvesicles, but does not completely normalize the process.